Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Biliary Tract Diseases

  Free Subscription


Articles published in Gut

Retrieve available abstracts of 65 articles:
HTML format



Single Articles


    October 2024
  1. ONNEKINK AM, Gorris M, Bekkali NL, Bos P, et al
    Endoscopic sphincterotomy to prevent post-ERCP pancreatitis after self-expandable metal stent placement for distal malignant biliary obstruction (SPHINX): a multicentre, randomised controlled trial.
    Gut. 2024 Oct 10:gutjnl-2024-332695. doi: 10.1136/gutjnl-2024-332695.
    PubMed     Abstract available


    September 2024
  2. ELURBIDE J, Colyn L, Latasa MU, Uriarte I, et al
    Identification of PRMT5 as a therapeutic target in cholangiocarcinoma.
    Gut. 2024 Sep 11:gutjnl-2024-332998. doi: 10.1136/gutjnl-2024-332998.
    PubMed     Abstract available


  3. COTE GA, Elmunzer BJ, Nitchie H, Kwon RS, et al
    Sphincterotomy for biliary sphincter of Oddi disorder and idiopathic acute recurrent pancreatitis: the RESPOnD longitudinal cohort.
    Gut. 2024 Sep 7:gutjnl-2024-332686. doi: 10.1136/gutjnl-2024-332686.
    PubMed     Abstract available


    August 2024
  4. SHI C, Hong J, Bai B, Li S, et al
    Morphological consistency between EUS and ERCP in diagnosing biliary sludge and microlithiasis.
    Gut. 2024 Aug 22:gutjnl-2024-332971. doi: 10.1136/gutjnl-2024-332971.
    PubMed    


  5. KHAN SA, Rushbrook SM, Kendall TJ, Zen Y, et al
    Guidelines Development Group for the British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma.
    Gut. 2024 Aug 19:gutjnl-2024-333359. doi: 10.1136/gutjnl-2024-333359.
    PubMed    


    July 2024
  6. HOV JR
    Sclerosing cholangitis and inflammatory bowel disease: a paradoxical relationship?
    Gut. 2024 Jul 17:gutjnl-2024-332835. doi: 10.1136/gutjnl-2024-332835.
    PubMed    


    June 2024
  7. KEGGENHOFF FL, Castven D, Becker D, Stojkovic S, et al
    PARP-1 selectively impairs KRAS-driven phenotypic and molecular features in intrahepatic cholangiocarcinoma.
    Gut. 2024 Jun 10:gutjnl-2023-331237. doi: 10.1136/gutjnl-2023-331237.
    PubMed     Abstract available


  8. BEDKE T, Stumme F, Tomczak M, Steglich B, et al
    Protective function of sclerosing cholangitis on IBD.
    Gut. 2024 Jun 5:gutjnl-2023-330856. doi: 10.1136/gutjnl-2023-330856.
    PubMed     Abstract available


    May 2024
  9. HE H, Chen S, Yu Y, Fan Z, et al
    Comprehensive single-cell analysis deciphered microenvironmental dynamics and immune regulator olfactomedin 4 in pathogenesis of gallbladder cancer.
    Gut. 2024 May 6:gutjnl-2023-331773. doi: 10.1136/gutjnl-2023-331773.
    PubMed     Abstract available


    April 2024

  10. Correction: Wnt signalling modulates transcribed-ultraconserved regions in hepatobiliary cancers.
    Gut. 2024 Apr 23:gutjnl-2016-312278corr1. doi: 10.1136/gutjnl-2016-312278.
    PubMed    


  11. FABRIS L, Pol J
    Mast cells and histamine in cholangiocarcinoma: exploring overlooked avenues for enhanced patient management.
    Gut. 2024 Apr 18:gutjnl-2024-332288. doi: 10.1136/gutjnl-2024-332288.
    PubMed    


  12. BANG JY, Arnoletti JP, Wagner A, Varadarajulu S, et al
    EUS-guided gallbladder drainage in acute cholecystitis: response to letter to the editor.
    Gut. 2024 Apr 12:gutjnl-2024-332342. doi: 10.1136/gutjnl-2024-332342.
    PubMed    


    March 2024
  13. HAYLER R, Tuft C, Fisher O
    Head of pancreas mass with biliary obstruction: an unusual cause.
    Gut. 2024 Mar 22:gutjnl-2024-332268. doi: 10.1136/gutjnl-2024-332268.
    PubMed    


  14. LARGHI A, van Wanrooij RLJ, Bronswijk M, Vanella G, et al
    Cholecystectomy following EUS-guided gallbladder drainage in patients with acute cholecystitis at high surgical risk: friend or foe?
    Gut. 2024 Mar 22:gutjnl-2024-332273. doi: 10.1136/gutjnl-2024-332273.
    PubMed    


  15. SHI A, Liu Z, Fan Z, Li K, et al
    Function of mast cell and bile-cholangiocarcinoma interplay in cholangiocarcinoma microenvironment.
    Gut. 2024 Mar 8:gutjnl-2023-331715. doi: 10.1136/gutjnl-2023-331715.
    PubMed     Abstract available


    January 2024
  16. TOTH R, Brindley PJ, Vaquero J
    Enhancing the opportunities for cholangiocarcinoma precision therapy.
    Gut. 2024 Jan 16:gutjnl-2023-331480. doi: 10.1136/gutjnl-2023-331480.
    PubMed    


    December 2023
  17. HANNEMANN A, Mayerle J, Beyer G
    Response to: Correspondence on 'Definition of age-dependent reference values for the diameter of the common bile duct and pancreatic duct on MRCP: still needed further discussion' by Wang et al.
    Gut. 2023 Dec 2:gutjnl-2023-331525. doi: 10.1136/gutjnl-2023-331525.
    PubMed    


    November 2023
  18. BANG JY, Arnoletti JP, Wagner A, Varadarajulu S, et al
    EUS-guided gallbladder drainage in acute cholecystitis: long-term problems with surgical approach.
    Gut. 2023 Nov 24:gutjnl-2023-331245. doi: 10.1136/gutjnl-2023-331245.
    PubMed    


  19. HONG JH, Yong CH, Heng HL, Chan JY, et al
    Integrative multiomics enhancer activity profiling identifies therapeutic vulnerabilities in cholangiocarcinoma of different etiologies.
    Gut. 2023 Nov 24:gutjnl-2023-330483. doi: 10.1136/gutjnl-2023-330483.
    PubMed     Abstract available


  20. FRITZSCHE JA, Smit E, Ponsioen CY, Voermans RP, et al
    Time to focus on the real potential benefit of endobiliary radiofrequency ablation: stent patency in patients with cholangiocarcinoma.
    Gut. 2023 Nov 21:gutjnl-2023-331359. doi: 10.1136/gutjnl-2023-331359.
    PubMed    


  21. CHEN L, Qiu W, Sun X, Gao M, et al
    Novel insights into causal effects of serum lipids and lipid-modifying targets on cholelithiasis.
    Gut. 2023 Nov 9:gutjnl-2023-330784. doi: 10.1136/gutjnl-2023-330784.
    PubMed     Abstract available


  22. NAKAGAMI S, Morita T, Yazumi S
    Rare cause of obstructive jaundice.
    Gut. 2023 Nov 6:gutjnl-2023-330496. doi: 10.1136/gutjnl-2023-330496.
    PubMed    


    October 2023
  23. ARECHEDERRA M, Casadei Gardini A, Raggi C
    More than shots in the dark: improving patient stratification to move closer to personalised therapies in intrahepatic cholangiocarcinoma.
    Gut. 2023 Oct 27:gutjnl-2023-331119. doi: 10.1136/gutjnl-2023-331119.
    PubMed    


  24. WANG F, Peng L, Liu Y
    Definition of age-dependent reference values for the diameter of the common bile duct and pancreatic duct on MRCP: still needed further discussion.
    Gut. 2023 Oct 10:gutjnl-2023-331163. doi: 10.1136/gutjnl-2023-331163.
    PubMed    


  25. LI JS, Fang J, Li ZS
    Endoluminal radiofrequency ablation prior to stenting for malignant biliary obstruction: really time to say goodbye?
    Gut. 2023 Oct 5:gutjnl-2023-331070. doi: 10.1136/gutjnl-2023-331070.
    PubMed    


  26. ZECHER BF, Ellinghaus D, Schloer S, Niehrs A, et al
    HLA-DPA1*02:01~B1*01:01 is a risk haplotype for primary sclerosing cholangitis mediating activation of NKp44+ NK cells.
    Gut. 2023 Oct 3:gutjnl-2023-329524. doi: 10.1136/gutjnl-2023-329524.
    PubMed     Abstract available


    September 2023
  27. RUSHBROOK SM, Kendall TJ, Zen Y, Albazaz R, et al
    British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma.
    Gut. 2023 Sep 28:gutjnl-2023-330029. doi: 10.1136/gutjnl-2023-330029.
    PubMed     Abstract available


  28. O'ROURKE CJ, Salati M, Rae C, Carpino G, et al
    Molecular portraits of patients with intrahepatic cholangiocarcinoma who diverge as rapid progressors or long survivors on chemotherapy.
    Gut. 2023 Sep 27:gutjnl-2023-330748. doi: 10.1136/gutjnl-2023-330748.
    PubMed     Abstract available


    August 2023
  29. JAROSOVA J, Zarivnijova L, Cibulkova I, Mares J, et al
    Endoluminal radiofrequency ablation in patients with malignant biliary obstruction: a randomised trial.
    Gut. 2023 Aug 31:gutjnl-2023-329700. doi: 10.1136/gutjnl-2023-329700.
    PubMed     Abstract available


    July 2023
  30. HE X, Gao N, Lv F, Wu F, et al
    Temporal trend of mortality in patients with cirrhosis with primary biliary cholangitis and primary sclerosing cholangitis during the COVID-19 pandemic.
    Gut. 2023 Jul 24:gutjnl-2023-330271. doi: 10.1136/gutjnl-2023-330271.
    PubMed    


    April 2023
  31. LEWINSKA M, Karhus ML, Ellegaard AG, Romero-Gomez M, et al
    Serum lipidome unravels a diagnostic potential in bile acid diarrhoea.
    Gut. 2023 Apr 18:gutjnl-2022-329213. doi: 10.1136/gutjnl-2022-329213.
    PubMed     Abstract available


  32. ZORNIAK M, Sirtl S, Beyer G, Mahajan UM, et al
    Consensus definition of sludge and microlithiasis as a possible cause of pancreatitis.
    Gut. 2023 Apr 18:gutjnl-2022-327955. doi: 10.1136/gutjnl-2022-327955.
    PubMed     Abstract available


    February 2023
  33. HALLENSLEBEN ND, Stassen PMC, Schepers NJ, Besselink MG, et al
    Patient selection for urgent endoscopic retrograde cholangio-pancreatography by endoscopic ultrasound in predicted severe acute biliary pancreatitis (APEC-2): a multicentre prospective study.
    Gut. 2023 Feb 27:gutjnl-2022-328258. doi: 10.1136/gutjnl-2022-328258.
    PubMed     Abstract available


  34. BEYER G, Kasprowicz F, Hannemann A, Aghdassi A, et al
    Definition of age-dependent reference values for the diameter of the common bile duct and pancreatic duct on MRCP: a population-based, cross-sectional cohort study.
    Gut. 2023 Feb 24:gutjnl-2021-326106. doi: 10.1136/gutjnl-2021-326106.
    PubMed     Abstract available


  35. MEMON SF, Jagtap N, Reddy DN
    Reply to Sachan and Mandavdhare.
    Gut. 2023;72:408-409.
    PubMed    


    July 2022
  36. MONIN MB, Baier L, Berger M, Gorny JG, et al
    SARS-CoV-2 vaccination in patients with GI and hepatobiliary carcinoma: a call for booster vaccination.
    Gut. 2022 Jul 26. pii: gutjnl-2022-328169. doi: 10.1136/gutjnl-2022-328169.
    PubMed    


    June 2022
  37. MORITA S, Duda DG
    Refining genetic and molecular classifications to facilitate breakthrough treatments in intrahepatic cholangiocarcinoma: are we there yet?
    Gut. 2022 Jun 30. pii: gutjnl-2022-327782. doi: 10.1136/gutjnl-2022-327782.
    PubMed    


  38. FICKERT P
    Bacteria as key players in primary sclerosing cholangitis?
    Gut. 2022 Jun 28. pii: gutjnl-2022-327876. doi: 10.1136/gutjnl-2022-327876.
    PubMed    


  39. AWONIYI M, Wang J, Ngo B, Meadows V, et al
    Protective and aggressive bacterial subsets and metabolites modify hepatobiliary inflammation and fibrosis in a murine model of PSC.
    Gut. 2022 Jun 15. pii: gutjnl-2021-326500. doi: 10.1136/gutjnl-2021-326500.
    PubMed     Abstract available


  40. MAKKI K, Brolin H, Petersen N, Henricsson M, et al
    6alpha-hydroxylated bile acids mediate TGR5 signalling to improve glucose metabolism upon dietary fiber supplementation in mice.
    Gut. 2022 Jun 13. pii: gutjnl-2021-326541. doi: 10.1136/gutjnl-2021-326541.
    PubMed     Abstract available


  41. ESSEILI MA
    Great escape: how infectious SARS-CoV-2 avoids inactivation by gastric acidity and intestinal bile.
    Gut. 2022 Jun 7. pii: gutjnl-2021-326624. doi: 10.1136/gutjnl-2021-326624.
    PubMed    


    May 2022
  42. MARTIN-SERRANO MA, Kepecs B, Torres-Martin M, Bramel ER, et al
    Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications.
    Gut. 2022 May 18. pii: gutjnl-2021-326514. doi: 10.1136/gutjnl-2021-326514.
    PubMed     Abstract available


  43. CAMILLERI M, Carlson P, BouSaba J, McKinzie S, et al
    Comparison of biochemical, microbial and mucosal mRNA expression in bile acid diarrhoea and irritable bowel syndrome with diarrhoea.
    Gut. 2022 May 17. pii: gutjnl-2022-327471. doi: 10.1136/gutjnl-2022-327471.
    PubMed     Abstract available


  44. MACIAS RIR, Cardinale V, Kendall TJ, Avila MA, et al
    Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions.
    Gut. 2022 May 17. pii: gutjnl-2022-327099. doi: 10.1136/gutjnl-2022-327099.
    PubMed     Abstract available


    April 2022
  45. ZHAO Y, Ren X, Lu J, He M, et al
    Mechanistic insight of SARS-CoV-2 infection using human hepatobiliary organoids.
    Gut. 2022 Apr 22. pii: gutjnl-2021-326617. doi: 10.1136/gutjnl-2021-326617.
    PubMed    


  46. VOSKENS C, Stoica D, Rosenberg M, Vitali F, et al
    Autologous regulatory T-cell transfer in refractory ulcerative colitis with concomitant primary sclerosing cholangitis.
    Gut. 2022 Apr 15. pii: gutjnl-2022-327075. doi: 10.1136/gutjnl-2022-327075.
    PubMed     Abstract available


    March 2022
  47. SACHAN A, Mandavdhare HS
    EUS versus MRCP in patients with intermediate risk of choledocholithiasis: clinical and statistical viewpoint.
    Gut. 2022 Mar 8. pii: gutjnl-2022-327239. doi: 10.1136/gutjnl-2022-327239.
    PubMed    


  48. PAGANO E, Elias JE, Schneditz G, Saveljeva S, et al
    Activation of the GPR35 pathway drives angiogenesis in the tumour microenvironment.
    Gut. 2022;71:509-520.
    PubMed     Abstract available


    February 2022
  49. JAGTAP N, Kumar JK, Chavan R, Basha J, et al
    EUS versus MRCP to perform ERCP in patients with intermediate likelihood of choledocholithiasis: a randomised controlled trial.
    Gut. 2022 Feb 10. pii: gutjnl-2021-325080. doi: 10.1136/gutjnl-2021-325080.
    PubMed     Abstract available


    January 2022
  50. VARGHESE C, Nayar M, Pandanaboyana S
    SARS-CoV-2 pandemic has impacted on patterns of aetiology for acute pancreatitis and management of gallstone pancreatitis in the UK.
    Gut. 2022 Jan 17. pii: gutjnl-2021-326845. doi: 10.1136/gutjnl-2021-326845.
    PubMed    


    December 2021
  51. AMPUERO J, Lucena A, Hernandez-Guerra M, Moreno-Moraleda I, et al
    Primary biliary cholangitis and SARS-CoV-2 infection: incidence, susceptibility and outcomes.
    Gut. 2021 Dec 7. pii: gutjnl-2021-325700. doi: 10.1136/gutjnl-2021-325700.
    PubMed    


    October 2021
  52. TRAUNER M, Fuchs CD
    Novel therapeutic targets for cholestatic and fatty liver disease.
    Gut. 2021 Oct 6. pii: gutjnl-2021-324305. doi: 10.1136/gutjnl-2021-324305.
    PubMed     Abstract available


  53. TRIVEDI PJ, Hirschfield GM
    Recent advances in clinical practice: epidemiology of autoimmune liver diseases.
    Gut. 2021;70:1989-2003.
    PubMed     Abstract available


    August 2021
  54. RUFFOLO LI, Jackson KM, Kuhlers PC, Dale BS, et al
    GM-CSF drives myelopoiesis, recruitment and polarisation of tumour-associated macrophages in cholangiocarcinoma and systemic blockade facilitates antitumour immunity.
    Gut. 2021 Aug 19. pii: gutjnl-2021-324109. doi: 10.1136/gutjnl-2021-324109.
    PubMed     Abstract available


    July 2021
  55. ARECHEDERRA M, Rullan M, Amat I, Oyon D, et al
    Next-generation sequencing of bile cell-free DNA for the early detection of patients with malignant biliary strictures.
    Gut. 2021 Jul 20. pii: gutjnl-2021-325178. doi: 10.1136/gutjnl-2021-325178.
    PubMed     Abstract available


  56. HALLENSLEBEN ND, Timmerhuis HC, Hollemans RA, Pocornie S, et al
    Optimal timing of cholecystectomy after necrotising biliary pancreatitis.
    Gut. 2021 Jul 16. pii: gutjnl-2021-324239. doi: 10.1136/gutjnl-2021-324239.
    PubMed     Abstract available


  57. YAMAO K, Kitano M, Chiba Y, Ogura T, et al
    Endoscopic placement of covered versus uncovered self-expandable metal stents for palliation of malignant gastric outlet obstruction.
    Gut. 2021;70:1244-1252.
    PubMed     Abstract available


    May 2021
  58. LIU Q, Li B, Li Y, Wei Y, et al
    Altered faecal microbiome and metabolome in IgG4-related sclerosing cholangitis and primary sclerosing cholangitis.
    Gut. 2021 May 25. pii: gutjnl-2020-323565. doi: 10.1136/gutjnl-2020-323565.
    PubMed     Abstract available


    February 2021
  59. FROMME M, Schneider CV, Pereira V, Hamesch K, et al
    Hepatobiliary phenotypes of adults with alpha-1 antitrypsin deficiency.
    Gut. 2021 Feb 25. pii: gutjnl-2020-323729. doi: 10.1136/gutjnl-2020-323729.
    PubMed     Abstract available


  60. AHMED W, Joshi D, Harrison P, Reffitt D, et al
    Intraductal bile duct stents should be prioritised for removal during the pandemic.
    Gut. 2021 Feb 1. pii: gutjnl-2021-324105. doi: 10.1136/gutjnl-2021-324105.
    PubMed    


    January 2021
  61. GOEPPERT B, Stichel D, Toth R, Fritzsche S, et al
    Integrative analysis reveals early and distinct genetic and epigenetic changes in intraductal papillary and tubulopapillary cholangiocarcinogenesis.
    Gut. 2021 Jan 19. pii: gutjnl-2020-322983. doi: 10.1136/gutjnl-2020-322983.
    PubMed     Abstract available


  62. AOKI S, Inoue K, Klein S, Halvorsen S, et al
    Placental growth factor promotes tumour desmoplasia and treatment resistance in intrahepatic cholangiocarcinoma.
    Gut. 2021 Jan 11. pii: gutjnl-2020-322493. doi: 10.1136/gutjnl-2020-322493.
    PubMed     Abstract available


    November 2020
  63. WAUTERS L, Ceulemans M, Lambaerts M, Accarie A, et al
    Association between duodenal bile salts and gastric emptying in patients with functional dyspepsia.
    Gut. 2020 Nov 25. pii: gutjnl-2020-323598. doi: 10.1136/gutjnl-2020-323598.
    PubMed    


  64. TAKEUCHI M, Vidigal PT, Guerra MT, Hundt MA, et al
    Neutrophils interact with cholangiocytes to cause cholestatic changes in alcoholic hepatitis.
    Gut. 2020 Nov 19. pii: gutjnl-2020-322540. doi: 10.1136/gutjnl-2020-322540.
    PubMed     Abstract available


  65. CALDERARO J, Kather JN
    Artificial intelligence-based pathology for gastrointestinal and hepatobiliary cancers.
    Gut. 2020 Nov 19. pii: gutjnl-2020-322880. doi: 10.1136/gutjnl-2020-322880.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Biliary Tract Diseases is free of charge.